Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aerin Medical Inc.

Positive Three-Year Follow-Up Results Confirm Long-Term Benefits of RhinAer® for Chronic Rhinitis
From Aerin Medical Inc.
Via Business Wire
New Two-Year Results Show Sustained Improvement in Chronic Rhinitis Symptoms Following a Single Procedure with Aerin Medical’s RhinAer®
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Announces Positive Two-year Outcomes from the VATRAC Trial of VivAer®
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Announces Sustained Clinical and Quality-of-Life Improvements Two Years After Chronic Rhinitis Treatment with RhinAer®
From Aerin Medical Inc.
Via Business Wire
Derrick Sung Joins Aerin Medical as Chief Financial Officer
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Announces New Positive Two-Year Results from VivAer® AERWAY Study
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Supports AAO-HNS Position Recognizing Nasal Valve Repair as a Distinct Procedure that Improves Nasal Obstruction Symptoms
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Announces CMS Set to Implement New CPT® Code for Temperature-Controlled Radiofrequency Repair of Nasal Valve Collapse
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Announces Establishment of a New CPT® Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Receives FDA Clearance of Next-Generation RhinAer® Stylus for Treatment of Patients with Chronic Rhinitis
From Aerin Medical Inc.
Via Business Wire
New 12-month Results from the VATRAC Trial Confirm Durable Efficacy of Aerin Medical’s VivAer® in Patients with Nasal Valve Collapse
From Aerin Medical Inc.
Via Business Wire
New Study of Aerin Medical’s RhinAer® Shows Positive Clinical and Quality-of-Life Results Following Treatment for Chronic Rhinitis
From Aerin Medical Inc.
Via Business Wire
New 12-month Results from RHINTRAC Randomized Controlled Trial Demonstrate Durable Safety and Efficacy of Aerin Medical’s RhinAer® for Treatment of Chronic Rhinitis
From Aerin Medical Inc.
Via Business Wire
Four-Year Results Show Aerin Medical’s VivAer® Treatment Provides Significant, Sustained Relief of Nasal Obstruction Symptoms
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Secures $60 Million in Equity Financing
From Aerin Medical Inc.
Via Business Wire
Aerin Medical’s RhinAer® Demonstrates Long-term Safety and Efficacy for Treatment of Chronic Rhinitis in Newly Published Two-year Study
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Announces Key Events at American Rhinologic Society and American Academy of Otolaryngology 2021 Meetings
From Aerin Medical Inc.
Via Business Wire
Results Published from RHINTRAC Randomized Controlled Trial Demonstrate Safety and Efficacy of Aerin Medical’s RhinAer® For Treatment of Chronic Rhinitis
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Announces Positive One-Year Results from RhinAer® Pivotal Trial for the Treatment of Chronic Rhinitis
From Aerin Medical Inc.
Via Business Wire
Aerin Medical Announces Results of Randomized Controlled Trial Supporting VivAer® for Treatment of Nasal Airway Obstruction With Nasal Valve Collapse
From Aerin Medical Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.